Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight
GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.
Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery
GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.
Can Anaxiom’s AVOS device open a new minimally invasive route in obesity treatment?
Find out how Anaxiom’s AVOS obesity device could reshape minimally invasive weight-loss treatment after early human results.
Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue
Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.
What Caliway’s CBL-514 and tirzepatide combination data could reveal about obesity treatment next
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Why TIXiMED’s TIX100 data highlights a growing therapeutic gap after GLP-1 weight-loss treatment
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
What Seaport Therapeutics’ Glyph platform reveals about the emerging science of gut lymphatic targeting
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.
What Kailera Therapeutics and Hengrui Pharma’s Phase 2 ribupatide results reveal about oral GLP-1 viability
Can oral ribupatide reshape obesity treatment economics and adoption? Explore what Phase 2 data mean for GLP-1 pill strategies.
Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.